The North America preeclampsia diagnostics market size was estimated at USD 400 million in 2025 and is projected to be worth around USD 532.37 million by 2035, growing at a CAGR of 2.9% from 2026 to 2035. The obese population has increased due to various health conditions, and it is visible in pregnant women. Following this, the need for a suitable diagnostic solution is accelerating the market expansion in healthcare. While the biomarkers' improving status is stimulating the clinicians' performance in preeclampsia predictions.

North America Preeclampsia Diagnostics Market Statical Scope

The trend of biomarker-related blood tests involves best-in-class significant ratios to accelerate robust preeclampsia diagnostics compared to any other traditional processes. The transition in proactive risk evaluation helps to set safety standards that support the advanced era of the market. This evaluation addresses the preeclampsia scenario in pregnant women. The automated immunoassay platforms double the strength of the market. The maternal health shift is stimulating more demand for effective specialized diagnostics.

The novel biomarker tests and market champions' innovative strategies are fuelling research in the molecular drivers and placental health. This initiative enhances the screening and forecasting of the tools. The tools play a supporting role in the market that brings great mechanisms to the diagnostic process, with more confidence in the healthcare providers' hands and knowledge. The different test types highlight accuracy in the market's testing space.

North America Preeclampsia Diagnostics Market Share, By Test Type, 2025 (%)

• Blood Tests – The blood tests segment acquired 64% of the share, driven by rising speculation of health deterioration, with sample type suggested by healthcare providers. In contrast, the need for precise biomarker identification is confirming more accuracy in the segmental market. This need is for analysing the pregnancy complications.
• Urine Analysis – The urine analysis segment held 36% of the share, with the popular preference of urine dipstick tests for bedside screening, which addresses the protein level in the urine. This is not a precision solution but a quick one for temporary guidance to the healthcare provider. Alongside the spot tests is an elevation in performance in proteinuria diagnosis, mainly for hypertensive pregnant women.

North America Preeclampsia Diagnostics Market Share, By Product, 2025 (%)

• Consumables – The consumables segment held 58% of the share due to the frequent prenatal visits that sped up the requirement of blood biomarkers. The accelerating use of immunoassay, reagents, and test strips is still a main source of revenue for the market due to the rising number of routine screenings.
• Instruments – The instruments segment covered 42% of the share with the convenient use of automated immunoassay analysers that promote the remarkable infrastructure of the hospital laboratories. The screening for preeclampsia is attracting smart interventions of specialized instruments in the market.

North America Preeclampsia Diagnostics Market Share, By End-user, 2025 (%)

• Hospitals – The hospitals segment acquired 56% of the share with the great development in the hospital laboratories that represent a suitable space for the advanced preeclampsia diagnostics. The
• modern diagnostic tools in hospitals, like multiplex and genetic assays is a boon for the segmental market.
• Specialty Clinics – The specialty clinics segment held 21% of the share with a great blend of specialty diagnostic centers that promote specialized prenatal care through the perfect blood test process. The modernized diagnostic technologies are the backbone of the segmental market, while development potential, reimbursement and comprehensive research are a perk for the visitors.
• Diagnostic Centers – The diagnostics centers segment held 15% of the share due to the growing interest of the FDA in blood-based biomarker tests, which have received a green signal from the FDA. The growing spending on novel tests stands as a commendable profit hype for the segmental market.

Competitive Landscape

The famous key players, such as PerkinElmer, Inc., F Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Metabolomic Diagnostics Ltd., Siemens Healthineers AG, and MOMM Diagnostics GmbH, act as specialists and smart developers for modernized laboratory diagnostic products. Thermo Fisher Scientific Inc. is one of the companies that focuses on improving specialized protein tests for preeclampsia. While the Metabolomic is sharpening its specialized skills for the screening tools for spotting metabolic hurdles for preeclampsia.

Recent Developments in the Market

In May 2026, Trinity Biotech plc welcomed Jerry Lydon to the post of North America's Commercial Operations. With his long-serving experience in the healthcare and diagnostic is elevating the expectations for the smart development and required promotion of the market with the best-in-class introduction of new products for the preeclampsia condition.

Segments Covered in the Report

By Test Type

• Blood Tests
• Urine Analysis

By Product

• Consumables
• Instruments

By End-user

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Others